The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Authors: Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao